Chinese Pharmaceutical Industry Enjoys Capital Influx
This article was originally published in PharmAsia News
Investment in China's medical sector in 2007 far exceeded previous years, and the number of venture capitalists eager to pump in funds is increasing. A funding consultant in Shanghai disclosed that as of last August, 12 medical-related enterprises had received nearly $200 million in investments - probably representing only the tip of the iceberg - compared with barely $100 million in 2006. More than half the funds went into the medical device domain, the hot favorite due to its short R&D cycle and growing demand propelled by an aging population. Health care services and medical outsourcing such as contract research are emerging as attractive bets. The quality improvement of local R&D capability and operations also contributed to the surge in investment. (Click here for more)
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.